Key Summary: On September 22, 2023, Two Seas Capital (10%) discussed joining the Board with CEO Mark Crossley but decided against the appointment. They continue discussions with management and the Board regarding their investment and may explore options to maximize shareholder value and improve corporate governance.Market Cap: $2.3 billion | Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders.
On September 22, 2023, Two Seas Capital (10%) discussed the possibility of joining the Board with Mark Crossley, the CEO of the company. However, it was decided not to proceed with this appointment. Two Seas Capital has ongoing discussions with the management and Board regarding their investment and may explore options to maximize shareholder value and improve corporate governance. Source
Comments